SLCO1B1 variants and the risk of antituberculosis drug-induced hepatotoxicity: a systematic review and meta-analysis

Pharmacogenomics. 2023 Dec;24(18):931-942. doi: 10.2217/pgs-2023-0168. Epub 2023 Nov 29.

Abstract

Aims: To evaluate the association between SLCO1B1 gene polymorphisms and susceptibility of antituberculosis drug-induced hepatotoxicity (ATDH). Methods: We searched the PubMed, Cochrane Library, Embase, Web of Science, Wan Fang and China National Knowledge Infrastructure database from inception to 2022. Results: Nine case-control studies with 1129 cases and 2203 controls were included. Among four SNPs reported in two or more studies, the final results indicated that SNP rs4149014 was significantly associated with decreased ATDH risk (dominant model, odds ratio: 0.73; 95% CI: 0.55-0.97; p = 0.03; allele model, odds ratio: 0.69; 95% CI: 0.55-0.86; p = 0.001), and the trial sequential analysis also confirmed this significant association. Conclusion: SLCO1B1 gene SNP rs4149014 was significantly associated with lower risk of ATDH susceptibility.

Keywords: SLCO1B1; antituberculosis drug-induced hepatotoxicity; meta-analysis; single nucleotide polymorphism.

Publication types

  • Meta-Analysis
  • Systematic Review
  • Review

MeSH terms

  • Alleles
  • Antitubercular Agents / adverse effects
  • Chemical and Drug Induced Liver Injury* / epidemiology
  • Chemical and Drug Induced Liver Injury* / genetics
  • Genetic Predisposition to Disease*
  • Genotype
  • Humans
  • Liver-Specific Organic Anion Transporter 1 / genetics
  • Polymorphism, Single Nucleotide / genetics

Substances

  • Antitubercular Agents
  • SLCO1B1 protein, human
  • Liver-Specific Organic Anion Transporter 1